Limitations
ALX has the ability to inhibit IkB kinases IKKε and TANK-binding kinase 1 (TBK1) besides GRK5. As such it may be argued that ALX is not a specific inhibitor of GRK. Nonetheless, this study assesses and emphasizes on the phenotypic outcomes of ALX and, or FSK therapies employed in the attempt to prevent the occurrence of PCH during CCS by modulating inflammatory responses.